$0.54
+0.04 (+8.54%)
Open$0.48
Previous Close$0.50
Day High$0.54
Day Low$0.45
52W High$23.49
52W Low$13.99
Volume—
Avg Volume696.5K
Market Cap14.36M
P/E Ratio48.03
EPS$0.39
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,511.2% upside
Current
$0.54
$0.54
Target
$24.85
$24.85
$15.48
$24.85 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.16M | 3.54M |
| Net Income | -163,651 | -194,157 | -147,578 |
| Profit Margin | -3.9% | -4.7% | -4.2% |
| EBITDA | -229,901 | -240,916 | -206,498 |
| Free Cash Flow | -133,630 | -165,029 | -157,801 |
| Rev Growth | +8.4% | +2.1% | +5.7% |
| Debt/Equity | 0.23 | 0.22 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |